ID   JHU-013
AC   CVCL_5988
SY   JHU 013; JHU013; JHU-O13; JHU-13; O13
DR   BTO; BTO:0003890
DR   BioSample; SAMN03151639
DR   Cosmic; 1122670
DR   Cosmic; 1530747
DR   PharmacoDB; JHU013_693_2019
DR   Wikidata; Q54898669
RX   PubMed=12925955;
RX   PubMed=12963126;
RX   PubMed=21868764;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a FaDu derivative (PubMed=21868764).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00404.
CC   Sequence variation: Homozygous for CDKN2A c.151-1G>T; splice acceptor mutation (from parent cell line).
CC   Sequence variation: Heterozygous for TP53 p.Arg248Leu (c.743G>T) and c.376-1G>A; splice acceptor mutation (from parent cell line).
ST   Source(s): PubMed=21868764
ST   Amelogenin: Not_detected
ST   CSF1PO: 12
ST   D13S317: 8,9
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 11,12
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C4043; Hypopharyngeal squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1218 ! FaDu
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 18
//
RX   PubMed=12925955; DOI=10.1002/ijc.11341;
RA   Minhas K.M., Singh B., Jiang W.W., Sidransky D., Califano J.A.;
RT   "Spindle assembly checkpoint defects and chromosomal instability in
RT   head and neck squamous cell carcinoma.";
RL   Int. J. Cancer 107:46-52(2003).
//
RX   PubMed=12963126; DOI=10.1016/S0304-3835(03)00344-6;
RA   Hoque M.O., Begum S., Sommer M., Lee T., Trink B., Ratovitski E.,
RA   Sidransky D.;
RT   "PUMA in head and neck cancer.";
RL   Cancer Lett. 199:75-81(2003).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//